A Review on Formulation Development

Abstract

Pharmaceutical formulation development is a fundamental component of drug product development that involves transforming an active pharmaceutical ingredient (API) into a safe, effective, stable, and patient-acceptable dosage form. The process integrates pre formulation studies, excipient selection, formulation design, manufacturing process optimization, analytical evaluation, stability assessment, and regulatory compliance. The physicochemical properties of the drug, including solubility, dissolution rate, particle size, polymorphism, permeability, and stability, significantly influence the selection of an appropriate dosage form and delivery strategy. Conventional dosage forms, such as tablets, capsules, suspensions, emulsions, creams, and injections, remain essential in pharmaceutical practice, while novel drug delivery systems offer opportunities to improve bioavailability, therapeutic effectiveness, patient compliance, and controlled drug release. Modern formulation development increasingly incorporates Quality by Design (QbD), Design of Experiments (DoE), risk assessment, and advanced analytical technologies to establish a systematic and science-based development process. Regulatory guidelines provide a framework for pharmaceutical development, quality risk management, and lifecycle quality assurance. Despite considerable progress, challenges related to poor aqueous solubility, drug instability, manufacturing scalability, cost, and regulatory complexity continue to influence product development. This review discusses the fundamental principles, stages, techniques, evaluation parameters, applications, challenges, and emerging trends in pharmaceutical formulation development. The integration of scientific understanding, innovative delivery technologies, and systematic quality management can contribute to the development of robust pharmaceutical products that meet patient needs and established quality standards.

Introduction

Pharmaceutical formulation development is the scientific process of designing and optimizing a drug product by combining an active pharmaceutical ingredient (API) with suitable excipients and manufacturing techniques. Its main aim is to produce a safe, effective, stable, and high-quality medicine that maintains its therapeutic performance throughout its shelf life.

An API may have limitations such as poor solubility, unpleasant taste, inadequate stability, poor flow properties, or low bioavailability. Formulation development addresses these problems through appropriate selection of dosage forms, excipients, manufacturing methods, and drug delivery systems.

1. Objectives of Pharmaceutical Formulation Development

The major objectives are:

1. To develop safe, effective, stable, and reproducible medicines.

2. To improve drug solubility, dissolution, and bioavailability.

3. To select suitable excipients.

4. To choose an appropriate dosage form and route of administration.

5. To achieve the desired drug release pattern.

6. To improve patient convenience and acceptability.

7. To establish suitable manufacturing and quality control procedures.

8. To ensure compatibility with packaging materials.

9. To meet pharmacopoeial and regulatory requirements.

10. To ensure consistent large-scale manufacturing.

2. Stages of Pharmaceutical Formulation Development

A. Drug candidate and target product identification

The first step involves identifying the therapeutic purpose, intended patient population, dose, route of administration, and desired duration of action. The Quality Target Product Profile (QTPP) defines the required characteristics of the final product.

B. Preformulation studies

These studies evaluate the physical and chemical properties of the API before formulation development.

• Physical characterization: Particle size, colour, crystal form, density, flow properties, and moisture content.

• Chemical characterization: Chemical stability, oxidation, hydrolysis, and degradation.

• Solubility and dissolution studies: Evaluate drug solubility and dissolution rate.

• Drug–excipient compatibility: Identify possible interactions between the API and excipients using techniques such as DSC, FTIR, and HPLC.

C. Selection of excipients

Excipients are added to improve the stability, manufacturing, appearance, and performance of pharmaceutical products.

Common categories include:

• Diluents: Lactose and microcrystalline cellulose.

• Binders: Povidone and starch.

• Disintegrants: Crospovidone and croscarmellose sodium.

• Lubricants: Magnesium stearate.

• Glidants: Colloidal silicon dioxide.

• Preservatives: Parabens.

• Antioxidants: Ascorbic acid.

• Surfactants: Polysorbates.

• Suspending agents: Xanthan gum.

D. Selection of dosage form

Dosage forms are selected according to drug properties, therapeutic requirements, and patient needs. Major types include:

• Solid: Tablets, capsules, powders, and granules.

• Liquid: Solutions, syrups, suspensions, and emulsions.

• Semisolid: Creams, ointments, gels, and pastes.

• Parenteral: Injections and infusions.

• Inhalation: Inhalers and nebulizer preparations.

• Transdermal: Drug-containing patches.

• Modified release: Sustained, delayed, and controlled-release preparations.

E. Formulation design and prototype development

Initial formulations are prepared using suitable manufacturing methods. For example, tablets may be prepared by direct compression, wet granulation, or dry granulation. Prototype batches are evaluated to identify suitable ingredient proportions and manufacturing conditions.

F. Formulation optimization

Optimization identifies the best formulation composition and processing conditions. Design of Experiments (DoE) is commonly used to study the effects of multiple variables.

Common experimental designs include factorial design, fractional factorial design, central composite design, Box–Behnken design, and mixture design.

G. Manufacturing process development

This stage involves developing and controlling manufacturing operations such as weighing, blending, granulation, drying, milling, compression, coating, filling, and packaging. Scale-up ensures that laboratory-developed formulations can be manufactured consistently on a commercial scale.

H. Quality control and stability testing

The final product undergoes quality testing to ensure that it meets established specifications. Stability studies determine whether the medicine maintains its quality, safety, and effectiveness during storage.

3. Conventional Pharmaceutical Formulations

A. Tablets

Tablets are widely used because they provide accurate dosing, convenient administration, portability, and economical manufacturing. Important factors include powder flow, compressibility, hardness, friability, disintegration, dissolution, and moisture sensitivity.

Common manufacturing methods include:

• Direct compression.

• Wet granulation.

• Dry granulation.

B. Capsules

Capsules contain drugs in powder, granule, pellet, or liquid form. They are designed to provide convenient drug administration and suitable drug release.

Important formulation considerations include:

• Uniformity of fill weight.

• Compatibility between drug and capsule shell.

• Moisture control.

• Drug release properties.

• Product stability.

Conclusion

Pharmaceutical formulation development is essential for converting an active pharmaceutical ingredient into a suitable drug product that meets predefined quality requirements and patient needs. The process involves preformulation characterization, excipient selection, dosage-form design, manufacturing development, optimization, quality evaluation, stability assessment, and regulatory compliance. Conventional formulations continue to play a major role in healthcare, while novel drug delivery systems offer additional approaches for addressing selected limitations of drug administration and release. Quality by Design, Design of Experiments, and risk-based quality management provide systematic frameworks for improving process understanding and product consistency. Future progress will depend on integrating formulation science with reliable analytical methods, advanced manufacturing technologies, appropriate computational tools, and sustainable development practices. Ultimately, successful formulation development must be demonstrated through robust evidence that the finished product meets its intended quality, safety, and performance requirements.

References

[1] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline Q8(R2): Pharmaceutical Development. 2009. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q8r2-pharmaceutical-development [2] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline Q9(R1): Quality Risk Management. 2023. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/q9r1-quality-risk-management [3] Acharya PC, Shetty S, Fernandes C, Suares D, Maheshwari R, Tekade RK. Preformulation in drug research and pharmaceutical product development. In: Advances in Pharmaceutical Product Development and Research. Academic Press; 2018. Available from: https://doi.org/10.1016/B978-0-12-814423-7.00001-0 [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline Q10: Pharmaceutical Quality System. 2008. Available from: https://www.ema.europa.eu/en/scientific-guidelines/ich-q10-pharmaceutical-quality-system [5] Comoglu T, Ozyilmaz ED. Pharmaceutical product development: a Quality by Design approach. In: Dosage Forms, Formulation Developments and Regulations. Academic Press; 2024. Available from: https://doi.org/10.1016/B978-0-323-91817-6.00001-2 [6] Quality by Design—Newer Technique for Pharmaceutical Product Development. Intelligent Pharmacy. 2024;2(1):122–129. Available from: https://doi.org/10.1016/j.ipha.2023.10.004 [7] Türkdo?an A, Alloush T, Demiralp B. Experimental design in pharmaceutical formulation development: achievements, limitations and the transition toward intelligent optimization. Scientia Pharmaceutica. 2026;94(2):38. Available from: https://doi.org/10.3390/scipharm94020038 [8] Aspects and implementation of pharmaceutical Quality by Design from conceptual frameworks to industrial applications. Pharmaceutics. 2025;17(5):623. Available from: https://doi.org/10.3390/pharmaceutics17050623

Copyright

Copyright © 2026 Ankit Goswami, Mr. Sujeet Pratap Singh, Mr. Pramod Mishra, Dr. Tarkeshwar Prasad Shukla. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.